具体实施方式
实施例1
(E)-3-[4-(吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸(AY1)的合成
1.1、2-氯甲基吡嗪的合成
在反应瓶中加入2-甲基吡嗪(4.8g,0.052mol)、CCl4(100mL),搅拌溶解后再加入N-氯代琥珀酰亚胺(7.0g,0.052mol)和过氧化苯甲酰(50.0mg)。反应混合物在白炽灯光照下,搅拌,回流反应12h左右,TLC[石油醚∶乙酸乙酯=2∶1(V/V)为展开剂]检测显示原料基本反应完全,反应液冷却至0℃,放置2h,过滤,滤饼用冷的CCl4(2×25mL)洗涤,合并滤液和洗涤液,于常温下减压蒸出四氯化碳(2-氯甲基吡嗪不稳定,温度升高会导致产物分解),残留物为淡棕色油状物,不经分离直接用于下一步反应。
1.2、(E)-3-[4-(吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸乙酯的合成
在反应瓶中加入阿魏酸乙酯(4.2g,0.019mol)、K2CO3(6.7g,0.048mol)、DMF(50mL),油浴加热至100℃,15min后加入上述2-氯甲基吡嗪(上步合成量)油状物,反应混合物于100℃下继续搅拌反应2h,TLC[石油醚∶乙酸乙酯=2∶1(V/V)为展开剂]检测显示反应基本完全。反应液冷却至室温,过滤除去KCl固体,往滤液中加入100mL水,用乙酸乙酯(3×70mL)萃取,合并乙酸乙酯层并用水(3×50mL)洗涤,经无水硫酸钠干燥,减压回收乙酸乙酯后的淡黄色固体,经硅胶柱分离,洗脱剂为石油醚∶乙酸乙酯=2∶1(V/V),收集产物,减压回收溶剂后,得(E)-3-[4-(吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸乙酯淡黄色晶体3.4g,收率为57.2%,m.p.101-102℃。
1H NMR(CDCl3,400MHz)δ:1.34(t,3H,J=7.2Hz,-COOCH2 CH 3 ),3.92(s,3H,-OCH3),4.27(q,2H,J=7.2Hz,-CH 2 CH3),5.19(s,2H,Pyr-CH2O-),6.33(d,1H,J=16.0Hz,2-CH=),6.93(d,1H,J=8.0Hz,5′-Ar-H),7.07(d,1H,J=8.0Hz,6′-Ar-H),7.10(s,1H,2′-Ar-H),7.62(d,1H,J=16.0Hz,3-CH=),8.55(s,1H,5″-Pyr-H),8.57(s,1H,6″-Pyr-H),8.87(s,1H,3″-Pyr-H);13CNMR(CDCl3,100.0MHz)δ:167.1,152.3,149.8,149.4,144.2,144.0,143.8,143.7,128.7,122.2,116.6,113.6,110.4,70.0,60.4,56.0,14.3;IR(KBr,cm-1)υ:3055.7,2981.6,2930.9,2834.5,1700.0,1627.2,1591.5,1514.9,1450.9,1424.9,1397.8,1237.1,1160.9,1038.6,961.0,860.5,810.7,750.4;ESI-Mass(+c)for C17H18N2O4:m/z(M++H)315.03.
1.3、(E)-3-[4-(吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸(AY1)的合成
反应式
在100mL圆底瓶中加入5mol/L的NaOH(10mL)、95%乙醇(20mL)、(E)-3-[4-(吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸乙酯(2.5g),室温搅拌,反应6h,TLC[石油醚∶乙酸乙酯=3∶2(V/V)为展开剂]检测显示反应完全,减压蒸出乙醇,反应液冷却下用6mol/L盐酸溶液调pH至4~5,析出固体,过滤,固体用冷水洗涤2次,抽干,用无水乙醇重结晶,60℃干燥8h得AY1淡黄色晶体1.9g,收率83.7%,m.p.192-193℃。
1H NMR(DMSO-d6,300MHz)δ:3.84(s,3H,-OCH3),5.29(s,2H,Pyr-CH 2 O-),6.46(d,1H,J=16.0Hz,2-CH=),7.11(d,1H,J=8.4Hz,5′-Ar-H),7.19(d,1H,J=8.4Hz,6′-Ar-H),7.36(d,1H,J=1.6Hz,2′-Ar-H),7.53(d,1H,J=16.0Hz,3-CH=),8.64(d,1H,J=2.4Hz,5″-Pyr-H),8.67(d,1H,J=2.4Hz,6″-Pyr-H),8.80(s,1H,3″-Pyr-H),12.24(brs,1H,-COOH);13C NMR(DMSO-d6,75.5MHz)δ:168.3,152.4,149.8,149.7,144.9,144.7,144.4,144.3,128.4,122.8,117.7,114.0,111.3,69.6,56.2;IR(KBr,cm-1)υ:3425.5,2934.7,1677.7,1626.5,1598.1,1512.1,1453.5,1420.7,1270.8,1138.7,1058.7,1022.6,841.6,808.3;ESI-Mass(+c)for C15H14N2O4:m/z(M++H)287.00.
实施例2
(E)-3-[4-(吡嗪-2-基-甲氧基)苯基]-丙烯酸(AY2)的合成
2.1、(E)-3-[4-(吡嗪-2-基-甲氧基)苯基]-丙烯酸乙酯的合成
按实施例1中1.1、1.2方法操作,得到(E)-3-[4-(吡嗪-2-基-甲氧基)苯基]-丙烯酸乙酯淡黄色晶体,收率44.2%,m.p.87-89℃。1H NMR(CDCl3,400MHz)δ:1.35(t,3H,J=7.2Hz,-COOCH2 CH 3 ),4.28(q,2H,J=7.2Hz,-CH 2 CH3),5.29(s,2H,Pyr-CH2O-),6.34(d,1H,J=16.0Hz,2-CH=),7.03(dd,2H,J=6.8,2.0Hz,3′,5′-Ar-H),7.51(dd,2H,J=6.8,2.0Hz,2′,6′-Ar-H),7.66(d,1H,J=16.0Hz,3-CH=),8.58~8.61(m,2H,5″,6″-Pyr-H),8.84(s,1H,3″-Pyr-H);13CNMR(CDCl3,100.0MHz)δ:167.2,159.7,152.2,144.1,143.9,143.7,129.8,128.1,116.4,115.2,69.0,60.4,14.3;IR(KBr,cm-1)υ:3051.0,2925.5,1700.1,1634.4,1600.9,1511.8,1451.3,1402.1,1313.3,1264.9,1173.0,1060.9,880.1,832.0;ESI-Mass(+c)for C16H16N2O3:m/z(M++H)285.08.
2.2、(E)-3-[4-(吡嗪-2-基-甲氧基)苯基]-丙烯酸(AY2)的合成
按实施例1中1.3方法操作,得到AY2白色晶体,收率91.5%,m.p.217-219℃。1H NMR(DMSO-d6,400MHz)δ:5.32(s,2H,Pyr-CH2O-),6.40(d,1H,J=16.0Hz,2-CH=),7.10(d,2H,J=8.8Hz,3′,5′-Ar-H),7.55(d,1H,J=16.0Hz,3-CH=),7.66(d,2H,J=8.8Hz,2′,6′-Ar-H),8.64~8.69(m,2H,5″,6″-Pyr-H),8.82(s,1H,3″-Pyr-H),12.24(brs,1H,-COOH);13C NMR(DMSO-d6,100.0MHz)δ:168.2,160.0,152.3,144.8,144.7,144.3,144.0,130.4,127.9,117.4,115.7,68.9;IR(KBr,cm-1)υ:3439.5,2922.3,1672.3,1600.4,1570.6,1511.8,1426.5,1402.1,1284.5,1240.6,1217.0,1173.7,1063.7,870.8,829.4;ESI-Mass(+c)for C14H12N2O3:m/z(M++H)257.03.
实施例3
4-(吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸(AY3)的合成
3.1、4-(吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸甲酯的合成
按实施例1中1.1、1.2方法操作,得到4-(吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸甲酯白色晶体,收率54.9%,m.p.127-130℃。1H NMR(CDCl3,400MHz)δ:3.92(s,3H,3-OCH3),3.98(s,3H,-COOCH3),5.38(s,2H,Pyr-CH2O-),6.97(d,1H,J=8.4Hz,5-Ar-H),7.61(d,1H,J=2.0Hz,2-Ar-H),7.66(d,1H,J=8.4Hz,6-Ar-H),8.57(d,1H,J=2.4Hz,5′-Pyr-H),8.59(d,1H,J=2.4Hz,6′-Pyr-H),8.88(s,1H,3′-Pyr-H);13C NMR(CDCl3,100.0MHz)δ:166.7,152.1,151.4,149.2,144.1,143.9,143.7,123.9,123.3,112.7,112.6,69.8,56.1,52.1;IR(KBr,cm-1)υ:2950.8,1713.4,1595.9,1514.0,1455.9,1436.1,1411.3,1347.2,1280.3,1220.4,1183.2,1134.3,1019.4,975.1,867.3,834.8,760.1;ESI-Mass(+c)for C14H14N2O4:m/z(M++H)275.09.
3.2、4-(吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸(AY3)的合成
按实施例1中1.3方法操作,得到AY3白色晶体,收率86.1%,m.p.232-234℃。1HNMR(DMSO-d6,400MHz)δ:3.78(s,3H,3-OCH3),5.24(s,2H,Pyr-CH2O-),6.97(d,1H,J=8.4Hz,5-Ar-H),7.44(dd,1H,J=8.4,1.6Hz,6-Ar-H),7.55(d,1H,J=1.6Hz,2-Ar-H),8.63(d,1H,J=2.4Hz,4′-Pyr-H),8.66(d,1H,J=2.4Hz,6′-Pyr-H),8.80(s,1H,3′-Pyr-H),-COOH(被DMSO中D2O交换);13C NMR(DMSO-d6,100.0MHz)δ:170.2,152.9,148.5,148.3,144.6,144.2,134.7,122.2,113.6,112.9,67.7,55.8;IR(KBr,cm-1)υ:3423.6,2916.9,1680.1,1647.2,1538.5,1415.6,1385.5,1273.7,1115.3,1067.5,1025.5,785.5;ESI-Mass(-c)for C13H12N2O4:m/z(M+-H)259.07.
实施例4、4-(吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸(AY4)的合成
4.1、4-(吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸乙酯的合成
按实施例1中1.1、1.2方法操作,得到4-(吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸乙酯灰白色晶体,收率54.9%,m.p.52-54℃。1H NMR(CDCl3,400MHz)δ:1.42(t,3H,J=7.2Hz,-COOCH2 CH 3 ),3.91(s,6H,3,5-OCH3),4.40(q,2H,J=7.2Hz,-CH 2 CH3),5.28(s,2H,Pyr-CH2O-),7.33(s,2H,2,6-Ar-H),8.54(s,2H,5′,6′-Pyr-H),9.07(s,1H,3′-Py-H);13C NMR(CDCl3,100.0MHz)δ:166.1,152.9,144.4,143.5,143.4,140.5,138.4,126.2,106.7,73.8,61.2,56.2,14.4;IR(KBr,cm-1)υ:2970.1,2916.9,1728.4,1599.3,1504.8,1466.9,1413.0,1368.5,1331.5,1254.3,1213.2,1124.8,1025.0,864.1,835.5,759.8;ESI-Mass(+c)for C16H18N2O5:m/z(M++H)319.12.
4.2、4-(吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸(AY4)的合成
按实施例1中1.3方法操作,得到AY4白色晶体,收率88.7%,m.p.184-185℃。1H NMR(DMSO-d6,400MHz)δ:3.80(s,6H,3,5-OCH3),5.14(s,2H,Pyr-CH2O-),7.24(s,2H,2,6-Ar-H),8.59(m,2H,5′,6′-Pyr-H),8.87(s,1H,3′-Py-H);13C NMR(CDCl3,100.0MHz)δ:167.3,153.1,144.6,144.5,144.2,140.2,126.9,106.9,73.7,56.5;IR(KBr,cm-1)υ:3428.9,2920.3,2837.3,1704.9,1579.2,1504.5,1467.2,1413.6,1333.4,1249.8,1188.0,1130.3,1066.1,1026.0,873.4,842.2,763.9,711.7;ESI-Mass(+c) for C14H14N2O5:m/z(M++H)291.04。
实施例5
3-(吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸(AY5)的合成
5.1、3-(吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸乙酯的合成
按实施例1中1.1、1.2方法操作,得到3-(吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸乙酯白色晶体,收率50.7%,m.p.96-98℃。1H NMR(CDCl3,400 MHz) δ:1.39(t,3H,J=7.2 Hz,-COOCH2 CH 3 ),3.97(s,3H,4-OCH3),4.36(q,2H,J=7.1 Hz,-CH 2 CH3),5.35(s,2H,Pyr-CH2O-),6.95(d,1H,J=8.4 Hz,5-Ar-H),7.66(d,1H,J=1.6 Hz,2-Ar-H),7.72(dd,1H,J=8.5 Hz,1.6 Hz,6-Ar-H),8.56(d,1H,J=2.4 Hz,3′-Pyr-H),8.59(d,1H,J=2.4 Hz,6′-Pyr-H),8.90(s,1H,3′-Pyr-H);13C NMR (CDCl3,100.0 MHz)δ:166.1,153.6,152.4,147.1,144.0,143.9,143.7,124.7,123.1,114.8,110.9,70.1,60.9,56.1,14.4;IR(KBr,cm-1)υ:3066.3,2972.4,2919.6,1702.3,1579.9,1514.5,1432.8,1279.0,1269.9,1221.8,1147.8,1111.4,1016.8,947.0 878.2,771.2;ESI-Mass(+c)for C15H16N2O4:m/z(M++H)289.12。
5.2、3-(吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸(AY5)的合成
按实施例1中1.3方法操作,得到AY5白色晶体,收率90.9%,m.p.238-240℃。1HNMR(DMSO-d6,400 MHz)δ:3.86(s,3H,4-OCH3),5.29(s,2H,Pyr-CH2O-),7.11(d,1H,J=8.4 Hz,5-Ar-H),7.57(s,1H,2-Ar-H),7.61(dd,1H,J=8.4,2.0 Hz,6-Ar-H),8.64(d,1H,J=2.4 Hz,5′-Pyr-H),8.68(d,1 H,J=2.4Hz,6′-Pyr-H),8.81(s,1H,3′-Pyr-H),-COOH(被DMSO中D2O交换);13C NMR(DMSO-d6,100.0 MHz)δ:167.4,153.5,152.5,147.3,144.8,144.7,144.3,124.6,123.5,114.6,112.0,69.7,56.3;IR(KBr,cm-1)υ:3440.3,2922.0,1702.4,1599.1,1516.3,1438.3,1274.6,1248.9,1 147.3,1109.6,1020.8,939.4,868.6,840.6,760.5;ESI-Mass(+c) for C13H12N2O4:m/z(M++H)260.97。
实施例6
4-(吡嗪-2-基-甲氧基)-苯甲酸(AY6)的合成
6.1、4-(吡嗪-2-基-甲氧基)苯甲酸乙酯的合成
按实施例1中1.1、1.2方法操作,得4-(吡嗪-2-基-甲氧基)苯甲酸乙酯淡黄色晶体,收率为51.4%,m.p.77-79℃。1H NMR(CDCl3,300MHz)δ:1.38(t,3H,J=7.1Hz,-CH2 CH 3 ),4.35(q,2H,J=7.1Hz,-CH 2 CH3),5.29(s,2H,Py-CH2O-),7.03(d,2H,J=8.8Hz,3,5-Ar-H),8.02(d,2H,J=8.8Hz,2,6-Ar-H),8.57~8.58(d,2H,5′,6′-Pyr-H),8.82(s,1H,3′-Pyr-H);13C NMR(CDCl3,75.5MHz)δ:166.1,161.7,152.0,144.2,144.0,143.7,131.7,123.7,114.4,69.0,60.8,14.4;IR(KBr,cm-1)υ:3080.7,2983.3,2910.7,1703.5,1606.0,1509.7,1479.0,1453.3,1419.5,1266.6,1170.3,1107.4,1058.2,1015.7,845.3,769.8;ESI-Mass(+c)for C14H14N2O3:m/z(M++H)258.94.
6.2、4-(吡嗪-2-基-甲氧基)苯甲酸(AY6)的合成
按实施例1中1.3方法操作,得AY6白色晶体,收率89.5%,m.p.218-219℃。1H NMR(DMSO-d6,400MHz)δ:5.35(s,2H,Pyr-CH2O-),7.15(d,2H,J=8.8Hz,3,5-Ar-H),7.91(d,2H,J=8.8Hz,2,6-Ar-H),8.65(d,1H,J=2.4Hz,5′-Pyr-H),8.68(d,1H,J=2.4Hz,6′-Pyr-H),8.83(s,1H,3′-Pyr-H),-COOH(被DMSO中D2O交换);13C NMR(DMSO-d6,100.0MHz)δ:167.4,162.0,152.1,144.8,114.7,144.3,131.9,124.1,115.1,69.0;IR(KBr,cm-1)υ:3429.1,3067.8,2921.2,1695.8,1604.9,1515.1,1454.7,1412.1,1258.5,1169.3,1109.0,1064.2,1033.5,855.7,769.7;ESI-Mass(+c)for C12H10N2O3:m/z(M++H)231.03.
实施例7
(E)-3-[4-(5-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸(AY7)的合成
7.1、2-氯甲基-5-甲基吡嗪的合成
在反应瓶中加入2,5-二甲基吡嗪(5.0g,0.046mol)、CCl4(100mL),搅拌溶解后再加入N-氯代琥珀酰亚胺(6.2g,0.046mol)和过氧化苯甲酰(50.0mg)。反应混合物在白炽灯光照下,搅拌,回流反应12h左右,TLC[石油醚∶乙酸乙酯=1∶1(V/V)为展开剂]检测显示原料基本反应完全,反应液冷却至0℃,放置2h,过滤,滤饼用冷的CCl4(2×25mL)洗涤,合并滤液和洗涤液,于常温下减压蒸出四氯化碳(2-氯甲基-5-甲基吡嗪不稳定,温度升高会导致产物分解),残留物为淡棕色油状物,不经分离直接用于下一步反应。
7.2、(E)-3-[4-(5-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸乙酯的合成
在反应瓶中加入阿魏酸乙酯(4.0g,0.018mol)、K2CO3(6.2g,0.044mol)、DMF(50mL),油浴加热至100℃,15min后加入上述2-氯甲基-5-甲基吡嗪(上步合成量)油状物,反应混合物于100℃下继续搅拌反应2h,TLC[V(石油醚)∶V(乙酸乙酯)=2∶1为展开剂]检测显示反应基本完全。反应液冷却至室温,过滤除去KCl固体,往滤液中加入100mL水,用乙酸乙酯(3×60mL)萃取,合并乙酸乙酯层并用水(3×50mL)洗涤,经无水硫酸钠干燥,减压回收乙酸乙酯后的淡黄色固体,经硅胶柱分离,洗脱剂为石油醚∶乙酸乙酯=2∶1(V/V),收集产物,减压回收溶剂后,得(E)-3-[4-(5-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸乙酯淡黄色晶体2.1g,收率为35.5%,m.p.135-136℃。
1H NMR(CDCl3,300MHz)δ:1.31(t,3H,J=7.2Hz,OCH2 CH 3 ),2.55(s,3H,-CH3),3.90(s,3H,-OCH3),4.23(q,2H,J=7.2Hz,OCH 2 CH3),5.26(s,2H,Pyr-CH2O-),6.28(d,1H,J=15.9Hz,2-CH=),6.88(d,1H,J=8.2Hz,5′-Ar-H),7.05(m,2H,2′,6′-Ar-H),7.58(d,1H,J=15.9Hz,3-CH=),8.41(s,1H,6″-Pyr-H),8.68(s,1H,3″-Pyr-H);13C-NMR(CDCl3,101MHz)δ:167.2,153.3,149.9,144.3,143.9,143.7,142.8,140.4,128.6,122.3,116.7,113.8,110.5,70.1,60.5,56.1,21.4,14.4;IR(KBr,cm-1)υ:3061.6,2985.2,2914.2,1705.2,1634.9,1596.1,1516.6,1425.5,1454.0,1425.4,1255.5,1154.0,1039.0,865.8,825.4;ESI-MS m/z for C18H20N2O4:329.03(M++H).
7.3、(E)-3-[4-(5-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸(AY7)的合成
在100mL圆底瓶中加入5mol/L的NaOH(10mL)、95%乙醇(20mL)、(E)-3-[4-(6-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸乙酯(1.7g),室温搅拌,反应6h,TLC[石油醚∶乙酸乙酯=2∶1(V/V)为展开剂]检测显示反应完全,减压蒸出乙醇,反应液冷却下用6mol/L盐酸溶液调pH至4~5,析出固体,过滤,固体用冷水洗涤2次,抽干,用无水乙醇重结晶,60℃干燥8h得AY7淡黄色晶体1.3g,收率83.6%,m.p.177-179℃。
1H NMR(DMSO-d6,400MHz)δ:2.50(s,3H,-CH3),3.84(s,3H,-OCH3),5.29(s,2H,Pyr-CH2O-),6.46(d,1H,J=16.0Hz,2-CH=),7.11(d,1H,J=8.2Hz,5′-Ar-H),7.21(dd,1H,J=8.2,2.0Hz,Ar-H),7.37(d,1H,J=2.0Hz,Ar-H),7.53(d,1H,J=16.0Hz,3-CH=),8.54(s,1H,6″-Pyr-H),8.58(s,1H,3″-Pyr-H),12.23(br s,1H,COOH);13C NMR(DMDO-d6,100MHz)δ:168.3,153.6,151.1,149.8,149.0,144.4,143.2,141.0,128.3,122.8,117.6,113.9,111.3,69.5,56.2,21.4;IR(KBr,cm-1)υ:3436.9,2931.3,1693.8,1627.4,1597.4,1514.0,1454.8,1424.1,1380.4,1267.2,1141.2,1032.6,806.9;ESI-MS m/z for C16H16N2O4:301.04(M++H).
实施例8
(E)-3-[4-(5-甲基-吡嗪-2-基-甲氧基)苯基]-丙烯酸(AY8)的合成
8.1、(E)-3-[4-(5-甲基-吡嗪-2-基-甲氧基)苯基]-丙烯酸乙酯的合成
按实施例7中7.1、7.2方法操作,得到(E)-3-[4-(5-甲基-吡嗪-2-基-甲氧基)苯基]-丙烯酸乙酯淡黄色晶体,收率36.2%,m.p.132-134℃。
1H NMR(CDCl3,400MHz)δ:1.35(t,3H,J=7.2Hz,-OCH2 CH 3 ),2.61(s,3H,CH3),4.27(q,2H,J=7.2Hz,-OCH 2 CH3),5.24(s,2H,Pyr-CH2O-),6.34(d,1H,J=16.0Hz,2-CH=),7.01(d,2H,J=8.4Hz,3′,5′-Ar-H),7.50(d,2H,J=8.4Hz,2′,6′-Ar-H),7.66(d,1H,J=16.0Hz,3-CH=),8.47(s,1H,6″-Pyr-H),8.68(s,1H,3″-Pyr-H);13C NMR(CDCl3,101MHz)δ:167.3,159.9,153.4,148.7,144.0,143.8,142.7,129.8,128.1,116.4,115.3,69.0,60.4,21.5,14.4;IR(KBr,cm-1)υ:2987.4,2905.7,1708.3,1633.1,1605.3,1515.6,1454.9,1372.0,1313.3,1259.2,1171.9,1035.2,993.5,881.0,826.1;ESI-MS m/z for C17H18N2O3:298.95(M++H).
8.2、(E)-3-[4-(5-甲基-吡嗪-2-基-甲氧基)苯基]-丙烯酸(AY8)的合成
按实施例7中7.3方法操作,得到AY8白色晶体,收率84.7%,m.p.228-230℃。
1H NMR(DMSO-d6,300MHz)δ:2.51(s,3H,CH3),5.26(s,2H,Pyr-CH2O-),6.39(d,1H,J=15.9Hz,2-CH=),7.09(d,2H,J=8.7Hz,3′,5′-Ar-H),7.54(d,1H,J=15.9Hz,3-CH=),7.64(d,2H,J=8.7Hz,2′,6′-Ar-H),8.56(s,1H,6″-Pyr-H),8.67(s,1H,3″-Pyr-H),12.21(br s,1H,COOH);13C NMR(DMDO-d6,75.5MHz)δ:168.3,160.0,153.6,148.9,144.2,143.7,143.2,130.4,127.9,117.8,115.7,68.8,21.38;IR(KBr,cm-1)υ:2913.4,2601.0,1677.2,1605.6,1576.1,1514.3,1428.9,1385.2,1334.6,1291.9,1223.6,1180.2,1055.7,994.6,963.0,875.9,827.5;ESI-MS m/z forC15H14N2O3:270.99(M++H).
实施例9
4-(5-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸(AY9)的合成
9.1、4-(5-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸甲酯的合成
按实施例7中7.1、7.2方法操作,得到4-(5-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸甲酯白色晶体,收率35.5%,m.p.89-91℃。
1H NMR(CDCl3,400MHz)δ:2.60(s,3H,CH3),3.89(s,3H,COOCH3),3.95(s,3H,OCH3),5.32(s,2H,Pyr-CH2O-),6.96(d,1H,J=8.4Hz,5′-Ar-H),7.60(d,1H,J=2.0Hz,2′-Ar-H),7.64(d,1H,J=8.4Hz,6′-Ar-H),8.44(s,1H,6″-Pyr-H),8.71(s,1H,3″-Pyr-H);13C NMR(CDCl3,100MHz)δ:166.7,153.3,151.5,150.8,149.2,148.6,143.6,142.7,140.4,123.3,112.6,69.8,56.1,52.0,21.4;IR(KBr,cm-1)υ:2946.0,1706.8,1645.9,1598.2,1516.7,1436.3,1374.6,1276.2,1222.6,1178.0,1144.1,1105.8,1036.7,985.3,876.9,819.7,760.7;ESI-MS m/z for C15H16N2O4:289.02(M++H).
9.2、4-(5-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸(AY9)的合成
按实施例7中7.3方法操作,得到AY9白色晶体,收率85.1%,m.p.152-154℃。
1H NMR(DMSO-d6,400MHz)δ:2.48(s,3H,CH3),3.78(s,3H,OCH3),5.23(s,2H,Pyr-CH2O-),7.14(d,1H,J=8.4Hz,5′-Ar-H),7.44(d,1H,J=2.0Hz,2′-Ar-H),7.52(d,1H,J=8.4Hz,6′-Ar-H),12.66(s,1H,COOH),8.51(s,1H,6″-Pyr-H),8.62(s,1H,3″-Pyr-H);13C NMR(DMDO-d6,100MHz)δ:167.5,153.8,151.8,151.0,149.2,144.5,143.3,141.0,123.5,113.3,112.9,69.6,56.1,21.4;IR(KBr,cm-1)υ:3439.3,2933.2,1700.9,1597.5,1519.4,1456.6,1419.9,1391.0,1344.5,1274.2,1225.3,1177.9,1137.9,1031.1,876.7,821.5,767.3,745.1;ESI-MS m/z forC14H14N2O4:275.05(M++H).
实施例10
4-(5-甲基-吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸(AY10)的合成
10.1、4-(5-甲基-吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸乙酯的合成
按实施例7中7.1、7.2方法操作,得到4-(5-甲基-吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸乙酯白色晶体,收率33.4%,m.p.68-70℃。
1H NMR(CDCl3,300MHz)δ:1.32(t,3H,J=7.2Hz,-OCH2 CH 3 ),2.48(s,3H,CH3),3.81(s,6H,-OCH3),4.30(q,2H,J-7.2Hz,-OCH 2 CH3),5.15(s,2H,Pyr-CH2O-),7.22(s,2H,2′,6′-Ar-H),8.31(s,1H,6″-Pyr-H),8.77(s,1H,3″-Pyr-H);13C NMR(CDCl3,75.5MHz)δ:166.1,152.9,149.9,143.34,143.31,143.2,141.0,126.1,106.7,73.9,61.1,56.2,21.3,14.4;IR(KBr,cm-1)υ:2983.9,2937.6,2872.2,2838.6,1710.5,1591.9,1535.6,1461.3,1501.9,1413.6,1366.1,1330.9,1225.1,1182.6,1131.1,1034.3,982.5,948.7,906.4,866.2,834.3,759.2,669.6;ESI-MS m/z forC17H20N2O5:332.98(M++H).
10.2、4-(5-甲基-吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸(AY10)的合成
按实施例7中7.3方法操作,得到AY10白色晶体,收率84.3%,m.p.167-169℃。
1H NMR(DMSO-d6,400MHz)δ:2.48(s,3H,CH3),3.80(s,6H,-OCH3),5.11(s,2H,Pyr-CH2O-),7.23(s,2H,2′,6′-Ar-H),8.47(s,1H,6″-Pyr-H),8.66(s,1H,3″-Pyr-H),12.96(br s,1H,COOH);13C NMR(DMDO-d6,101MHz)δ:167.9,153.2,153.1,143.9,143.6,143.5,141.2,126.9,107.0,72.4,56.5,21.4;IR(KBr,cm-1)υ:2948.1,1687.6,1592.3,1536.9,1505.1,1459.8,1419.9,1334.8,1282.5,1239.9,1183.0,1132.8,1037.6,938.9,864.5,814.9,764.9,725.1;ESI-MS m/z forC15H16N2O5:304.99(M++H).
实施例11
3-(5-甲基-吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸(AY11)的合成
11.1、3-(5-甲基-吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸乙酯的合成
按实施例7中7.1、7.2方法操作,得到3-(5-甲基-吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸乙酯淡黄色晶体,收率30.7%,m.p.102-104℃。
1H NMR(CDCl3,400MHz)δ:1.39(t,3H,J=7.2Hz,-OCH2 CH 3 ),2.60(s,3H,CH3),3.96(s,3H,OCH3),4.35(q,2H,J=7.2Hz,-OCH 2 CH3),5.31(s,2H,Pyr-CH2O-),6.94(d,1H,J=8.4Hz,5′-Ar-H),7.66(d,1H,J=2.0Hz,2′-Ar-H),7.74(dd,J=8.4,2.0Hz,1H,6′-Ar-H),8.47(s,1H,6″-Pyr-H),8.74(s,1H,3″-Pyr-H);13C NMR(CDCl3,100MHz)δ:166.1,153.6,153.1,148.9,147.2,143.7,142.7,124.6,123.1,114.8,110.8,70.0,60.8,56.0,21.4,14.4;IR(KBr,cm-1)υ:3081.6,2974.2,2932.4,2838.9,1713.2,1595.6,1515.5,1431.6,1384.2,1335.9,1287.1,1247.1,1105.3,1027.6,942.9,875.5,819.1,787.4,758.6,723.2;ESI-MS m/z for C16H18N2O4:303.02(M++H).
11.2、3-(5-甲基-吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸(AY11)的合成
按实施例7中7.3方法操作,得到AY11白色晶体,收率87.1%,m.p.202-204℃。
1H NMR(DMSO-d6,400MHz)δ:2.51(s,3H,CH3),3.85(s,3H,OCH3),5.24(s,2H,Pyr-CH2O-),7.09(d,1H,J=8.4Hz,5′-Ar-H),7.56(d,1H,J=2.0Hz,2′-Ar-H),7.60(dd,1H,J=8.4,2.0Hz,6′-Ar-H),8.57(s,1H,6″-Pyr-H),8.66(s,1H,3″-Pyr-H),12.68(br s,1H,COOH);13C NMR(DMDO-d6,100MHz)δ:167.4,153.6,153.5,149.1,147.4,144.2,143.2,124.4,123.5,114.6,111.9,69.6,56.3,21.4;IR(KBr,cm-1)υ:3140.3,2948.3,1703.2,1595.8,1517.2,1435.7,1271.3,1217.1,1183.4,1147.8,1113.4,1022.3,876.4,842.4,773.9,745.2;ESI-MS m/z forC14H14N2O4:275.04(M++H).
实施例12
4-(5-甲基-吡嗪-2-基-甲氧基)苯甲酸(AY12)的合成
12.1、4-(5-甲基-吡嗪-2-基甲氧基)苯甲酸乙酯的合成
按实施例7中7.1、7.2方法操作,得到4-(5-甲基-吡嗪-2-基甲氧基)苯甲酸乙酯类白色晶体,收率40.8%,m.p.82-84℃。
1H NMR(CDCl3,400MHz)δ:1.40(t,3H,J=7.2Hz,-OCH2 CH 3 ),2.61(s,3H,CH3),4.37(q,2H,J=7.2Hz,-OCH 2 CH3),5.27(s,2H,Pyr-CH2O-),7.04(d,2H,J=8.8Hz,3′,5′-Ar-H),8.03(d,2H,J=8.8Hz,2′,6′-Ar-H),8.48(s,1H,6″-Pyr-H),8.69(s,1H,3″-Pyr-H);13C-NMR(CDCl3,101MHz)δ:166.2,161.7,153.4,148.5,143.7,142.6,131.6,123.8,114.4,68.9,60.7,21.4,14.4;IR(KBr,cm-1)υ:2928.7,1707.6,1605.0,1513.5,1455.4,1256.8,1175.7,1126.5,1052.0,1029.3,863.9,768.9;ESI-MS m/z for C15H16N2O3:273.02(M++H).
12.2、4-(5-甲基-吡嗪-2-基甲氧基)苯甲酸(AY12)的合成
按实施例7中7.3方法操作,得到AY12白色晶体,收率85.8%,m.p.234-236℃。
1H NMR(DMSO-d6,400MHz)δ:2.52(s,3H,CH3),5.29(s,2H,Pyr-CH2O-),7.13(d,2H,J=8.8Hz,3′,5′-Ar-H),7.90(d,2H,J=8.8Hz,2′,6′-Ar-H),8.57(s,1H,6″-Pyr-H),8.68(s,1H,3″-Pyr-H),12.66(br s,1H,COOH);13C NMR(DMDO-d6,100MHz)δ:167.4,162.0,153.7,148.7,144.2,143.2,131.8,124.0,115.1,68.9,21.4;IR(KBr,cm-1)υ:3423.6,2919.2,1675.4,1605.4,1515.1,1425.4,1303.1,1261.6,1175.0,1126.0,1052.3,878.2;ESI-MS m/z for C13H12N2O3:245.02(M++H).
实施例13
(E)-3-[4-(6-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸(AY13)的合成
13.1、2-氯甲基-6-甲基吡嗪的合成
在反应瓶中加入2,6-二甲基吡嗪(5.0g,0.046mol)、CCl4(100mL),搅拌溶解后再加入N-氯代琥珀酰亚胺(6.2g,0.046mol)和过氧化苯甲酰(50.0mg)。反应混合物在白炽灯光照下,搅拌,回流反应12h左右,TLC[石油醚∶乙酸乙酯=1∶1(V/V)为展开剂]检测显示原料基本反应完全,反应液冷却至0℃,放置2h,过滤,滤饼用冷的CCl4(2×25mL)洗涤,合并滤液和洗涤液,于常温下减压蒸出四氯化碳(2-氯甲基-6-甲基吡嗪不稳定,温度升高会导致产物分解),残留物为淡棕色油状物,不经分离直接用于下一步反应。
13.2、(E)-3-[4-(6-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸乙酯的合成
在反应瓶中加入阿魏酸乙酯(4.0g,0.018mol)、K2CO3(6.2g,0.044mol)、DMF(50mL),油浴加热至100℃,15min后加入上述2-氯甲基-6-甲基吡嗪(上步合成量)油状物,反应混合物于100℃下继续搅拌反应2h,TLC[石油醚∶乙酸乙酯=2∶1(V/V)为展开剂]检测显示反应基本完全。反应液冷却至室温,过滤除去KCl固体,往滤液中加入100mL水,用乙酸乙酯乙酸乙酯后的淡黄色固体,经硅胶柱分离,洗脱剂为石油醚∶乙酸乙酯=2∶1(V/V),收集产物,减压回收溶剂后,得(E)-3-[4-(6-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸乙酯淡黄色晶体1.9g,收率为32.2%,m.p.102-104℃。
1H NMR(CDCl3,400MHz)δ:1.33(t,3H,J=7.2Hz,OCH2 CH 3 ),2.59(s,3H,CH3),3.93(s,3H,OCH3),4.26(q,2H,J=7.2Hz,OCH 2 CH3),5.29(s,2H,Pyr-CH2O-),6.32(d,1H,J=16.0Hz,2-CH=),6.90(d,1H,J=8.4Hz,5′-Ar-H),7.07(d,1H,J=8.4Hz,6′-Ar-H),7.09(s,2H,2′-Ar-H),7.61(d,1H,J=16.0Hz,3-CH=),8.42(s,1H,5″-Pyr-H),8.64(s,1H,3″-Pyr-H);13C NMR(CDCl3,100MHz)δ:167.1,153.0,151.0,149.8,149.6,144.2,143.8,140.3,128.5,122.2,116.6,113.5,110.4,70.0,60.4,55.9,21.4,14.3;IR(KBr,cm-1)υ:3059.7,2984.8,2906.7,1706.4,1636.7,1595.5,1514.6,1425.2,1465.7,1367.0,1262.4,1150.6,1180.8,1029.4,846.9,799.6;ESI-MS m/zfor C18H20N2O4:329.22(M++H).
13.3、(E)-3-[4-(6-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸(AY13)的合成
在100mL圆底瓶中加入5mol/L的NaOH(10mL)、95%乙醇(20mL)、(E)-3-[4-(6-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯基]-丙烯酸乙酯(1.5g),室温搅拌,反应6h,TLC[石油醚∶乙酸乙酯=2∶1(V/V)为展开剂]检测显示反应完全,减压蒸出乙醇,反应液冷却下用6mol/L盐酸溶液调pH至4~5,析出固体,过滤,固体用冷水洗涤2次,抽干,用无水乙醇重结晶,60℃干燥8h得AY13淡黄色晶体1.1g,收率80.7%,m.p.117-119℃。
1H NMR(DMSO-d6,400MHz)δ:2.51(s,3H,CH3),3.83(s,3H,OCH3),5.22(s,2H,Pyr-CH2O-),6.46(d,1H,J=16.0Hz,),7.09(d,1H,J=8.4Hz,5′-Ar-H),7.20(d,1H,J=8.4Hz,6′-Ar-H),7.36(s,1H,2′-Ar-H),7.52(d,1H,J=16.0Hz,3-CH=),8.52(s,1H,5″-Pyr-H),8.57(s,1H,3″-Pyr-H);13C NMR(DMSO-d6,100MHz)δ:168.3,153.5,151.1,149.8,144.4,144.3,140.9,128.4,122.8,117.7,113.9,111.3,69.6,56.2,21.5;IR(KBr,cm-1)υ:2922.9,2611.5,1698.6,1630.1,1598.4,1516.0,1423.1,1365.2,1252.8,1156.7,1027.9,877.6,803.1;ESI-MS m/z for C16H16N2O4:301.05(M++H).
实施例14
(E)-3-[4-(6-甲基-吡嗪-2-基-甲氧基)苯基]-丙烯酸(AY14)的合成
14.1、(E)-3-[4-(6-甲基-吡嗪-2-基-甲氧基)苯基]-丙烯酸乙酯的合成
按实施例13中13.1、13.2方法操作,得到(E)-3-[4-(6-甲基-吡嗪-2-基-甲氧基)苯基]-丙烯酸乙酯白色晶体,收率36.3%,m.p.125-127℃。
1H NMR(CDCl3,300MHz)δ:1.35(t,3H,J=7.2Hz,-CH2 CH 3 ),2.61(s,3H,CH3),4.27(q,2H,J=7.2Hz,OCH 2 CH3),5.24(s,2H,Pyr-CH2O-),6.34(d,1H,J=16.0Hz,2-CH=),7.02(d,2H,J=8.2Hz,3′,5′-Ar-H),7.50(d,2H,J=8.2Hz,2′,6′-Ar-H),7.65(d,1H,J=16.0Hz,3-CH=),8.45(s,1H,5″-Pyr-H),8.62(s,1H,3″-Pyr-H);13C NMR(DMSO-d6,75.5MHz)δ:167.2,159.9,153.2,150.9,144.0,143.9,140.4,129.8,128.1,116.4,115.2,69.2,60.4,21.6,14.4;IR(KBr)υ:2987.7,1704.5,1704.6,1632.7,1602.2,1535.9,1510.6,1455.3,1423.2,1366.7,1288.3,1245.6,1208.4,1174.7,1055.9,1024.6,875.8,825.5,741.3,626.4,517.3,442.8cm-1;ESI-MS m/z forC17H18N2O3:298.97(M++H).
14.2、(E)-3-[4-(6-甲基-吡嗪-2-基-甲氧基)苯基]-丙烯酸(AY14)的合成
按实施例13中13.3方法操作,得到AY14白色晶体,收率90.5%,m.p.177-179℃。
1H NMR(DMSO-d6,400MHz)δ:2.52(d,3H,CH3),5.25(s,2H,Pyr-CH2O-),6.40(d,1H,J=16.0Hz,2-CH=),7.21(d,2H,J=8.8Hz,3′,5′-Ar-H),7.55(d,1H,J=16.0Hz,3-CH=),7.65(d,2H,J=8.8Hz,2′,6′-Ar-H),8.52(s,1H,5″-Pyr-H),8.60(s,1H,3″-Pyr-H),12.26(br s,1H,COOH);13C NMR(DMSO-d6,75.5MHz)δ:168.2,160.1,153.6,151.0,144.4,144.0,140.9,130.4,127.9,117.4,115.6,69.0,21.5;IR(KBr,cm-1)υ:3440.3,2919.7,1688.8,1605.5,1541.1,1513.2,1424.9,1303.2,1244.3,1170.9,1067.6,981.1,873.0,821.4;ESI-MS m/z for C15H14N2O3:271.07(M++H).
实施例15
4-(6-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸(AY15)的合成
15.1、4-(6-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸甲酯的合成
按实施例13中13.1、13.2方法操作,得到4-(6-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸甲酯白色晶体,收率41.9%,m.p.125-127℃。
1H NMR(CDCl3,400MHz)δ:2.60(s,3H,CH3),3.9(s,3H,-OCH3),3.96(s,3H,COOCH3),5.32(s,2H,Pyr-CH2O-),6.94(d,1H,J=8.8Hz,5′-Ar-H),7.59(d,1H,J=2.0Hz,2′-Ar-H),7.64(d,1H,J=8.8Hz,6′-Ar-H),8.43(s,1H,5″-Pyr-H),8.64(s,1H,3″-Pyr-H);13C NMR(CDCl3,100MHz)δ:166.7,153.1,151.5,150.8,149.2,143.8,140.3,123.7,123.3,112.6,112.5,69.9,56.1,52.0,21.5;IR(KBr,cm-1)υ:3079.2,3001.2,2944.6,1704.8,1598.3,1516.6,1424.8,1343.3,1371.6,1274.7,1222.7,1177.6,1139.9,1105.3,1031.3,981.9,879.9,820.6,762.3,650.5,562.9,472.6,441.0;ESI-MS m/z for C15H16N2O4:289.09(M++H).
15.2、4-(6-甲基-吡嗪-2-基-甲氧基)-3-甲氧基苯甲酸(AY15)的合成
按实施例13中13.3方法操作,得到AY15白色晶体,收率91.2%,m.p.190-192℃。
1H NMR(DMSO-d6,400MHz)δ:2.51(s,3H,CH3),3.83(s,3H,-OCH3),5.26(s,2H,Pyr-CH2O-),7.18(d,1H,J=8.4Hz,5′-Ar-H),7.49(d,1H,J=1.6Hz,2′-Ar-H),7.55(d,1H,J=8.4Hz,6′-Ar-H),8.54(s,1H,5″-Pyr-H),8.59(s,1H,3″-Pyr-H),12.77(brs,1H,-COOH);13C NMR(DMSO-d6,100MHz)δ:167.5,153.6,151.7,150.9,149.1,144.4,140.9,124.3,123.5,113.1,112.8,69.6,56.1,21.5;IR(KBr,cm-1)υ:2933.3,2803.6,1696.7,1654.3,1598.5,1516.0,1428.8,1342.5,1340.2,1270.8,1223.8,1171.9,1140.2,1111.3,1030.5,879.7,823.5,745.6,650.3,588.8;ESI-MSm/z for C14H14N2O4:275.04(M++H).
实施例16
4-(6-甲基-吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸(AY16)的合成
16.1、4-(6-甲基-吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸乙酯的合成
按实施例13中13.1、13.2方法操作,得到4-(6-甲基-吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸乙酯白色晶体,收率35.9%,m.p.91-93℃。
1H NMR(CDCl3,300MHz)δ:1.42(t,3H,J=7.2Hz,OCH2 CH 3 ),2.58(s,3H,CH3),3.91(s,6H,-OCH3),4.40(q,2H,J=7.2Hz,OCH 2 CH3),5.25(s,2H,Pyr-CH2O-),7.33(s,2H,2′,6′-Ar-H),8.41(s,1H,5″-Pyr-H),8.85(s,1H,3″-Pyr-H);13C NMR(CDCl3,75.5MHz)δ:166.3,153.0,152.6,152.3,143.4,141.1,140.9,126.2,106.8,74.1,61.3,56.3,21.6,14.5;IR(KBr,cm-1)υ:2983.0,2938.4,1708.8,1593.6,1538.5,1505.2,1461.3,1413.7,1364.8,1330.9,1255.9,1227.8,1183.0,1129.2,1039.9,986.2,870.2,760.4,670.1,597,9;ESI-MS m/z for C17H20N2O5:332.98(M++H).
16.2、4-(6-甲基-吡嗪-2-基-甲氧基)-3,5-二甲氧基苯甲酸(AY16)的合成
按实施例13中13.3方法操作,得到AY16白色晶体,收率86.5%,m.p.182-185℃。
1H NMR(DMSO-d6,400MHz)δ:2.49(s,3H,CH3),3.81(s,6H,3,5-OCH3),5.25(s,2H,Pyr-CH2O-),7.25(s,2H,2′,6′-Ar-H),8.50(s,1H,5″-Pyr-H),8.66(s,1H,3″-Pyr-H),13.01(br s,1H,COOH),;13C NMR(DMSO-d6,100MHz,)δ:166.8,152.6,152.5,151.4,143.4,140.7,126.4,106.5,73.2,56.0,20.9;IR(KBr,cm-1)υ:3431.2,2943.0,1715.8,1595.3,1507.0,1460.3,1415.8,1333.0,1257.5,1226.6,1130.8,1048.7,868.9,762.6,709.8;ESI-MS m/z for C15H16N2O5:305.01(M++H).
实施例17
3-(6-甲基-吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸(AY17)的合成
171、3-(6-甲基-吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸乙酯的合成
按实施例13中13.1、13.2方法操作,得到3-(6-甲基-吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸乙酯白色晶体,收率34.1%,m.p.91-93℃。
1H NMR(CDCl3,400MHz)δ:1.39(t,3H,J=7.2Hz,OCH2 CH 3 ),2.61(s,3H,CH3),3.97(s,3H,OCH3),4.35(q,2H,J=7.2Hz,OCH 2 CH3),5.31(s,2H,Pyr-CH2O-),6.95(d,1H,J=8.2Hz,5′-Ar-H),7.66(d,1H,J=1.6Hz,2′-Ar-H),7.75(d,J=8.2,1.6Hz,1H,6′-Ar-H),8.44(s,1H,5″-Pyr-H),8.68(s,1H,3″-Pyr-H);13C NMR(CDCl3,100MHz)δ:166.1,153.6,153.1,151.1,147.2,143.7,140.3,124.6,123.1,114.7,110.9,70.2,60.8,56.0,21.5,14.4;IR(KBr,cm-1)υ:3090.1,2964.4,1708.6,1596.0,1516.1,1417.3,1343.7,1369.2,1229.5,1273.6,1218.2,1173.7,1130.5,1101.3,1052.5,1017.1,936.9,872.5,828.2,791.0,762.4,630.9,562.8,477.5,441.9;ESI-MS m/zfor C16H18N2O4:303.11(M++H).
17.2、3-(6-甲基-吡嗪-2-基-甲氧基)-4-甲氧基苯甲酸(AY17)的合成
按实施例13中13.3方法操作,得到AY17白色晶体,收率84.7%,m.p.205-207℃。
1H NMR(DMSO-d6,400MHz)δ:2.51(s,3H,CH3),3.86(s,3H,OCH3),5.23(s,2H,Pyr-CH2O-),7.11(d,1H,J=8.8Hz,5′-Ar-H),7.58(d,1H,J=2.0Hz,2′-Ar-H),7.61(dd,1H,J=8.8,2.0Hz,6′-Ar-H),8.54(s,1H,5″-Pyr-H),8.59(s,1H,3″-Pyr-H),12.67(s,1H,COOH);13C NMR(DMSO-d6,100MHz,)δ:167.4,153.5,153.4,151.2,147.4,144.4,141.0,124.5,123.4,114.6,111.9,69.8,56.3,21.5;IR(KBr)υ:2920.0,1644.4,1515.4,1423.8,1265.7,1111.8,877.9,797.2,556.7cm-1;ESI-MS m/z for C14H14N2O4:275.04(M++H).
实施例18
4-(6-甲基-吡嗪-2-基-甲氧基)-苯甲酸(AY18)的合成
18.1、4-(6-甲基-吡嗪-2-基甲氧基)苯甲酸乙酯的合成
按实施例13中13.1、13.2方法操作,得到4-(6-甲基-吡嗪-2-基甲氧基)苯甲酸乙酯类白色晶体,收率38.4%,m.p.57-59℃。
1H NMR(CDCl3,400MHz)δ:1.39(t,J=7.2Hz,3H,OCH2 CH 3 ),2.61(s,3H,CH3),4.36(q,2H,J=7.2Hz,OCH 2 CH3),5.25(s,2H,Pyr-CH2O-),7.03(dd,2H,J=8.8,2.0Hz,3′,5′-Ar-H),8.02(d,2H,J=8.8Hz,2′,6′-Ar-H),8.45(s,1H,5″-Pyr-H),8.61(s,1H,3″-Pyr-H);13C NMR(CDCl3,101MHz)δ:166.2,161.7,153.2,150.6,143.9,140.3,131.7,123.8,114.3,69.1,60.7,21.5,14.4;IR(KBr,cm-1)υ:2989.2,2910.0,2362.6,2111.5,1797.0,1710.0,1604.4,1537.3,1507.9,1454.4,1421.3,1367.9,1280.3,1247.7,1162.1,1100.7,1057.2,1016.7,852.7,771.6,738.1,693.5,655.0,559.9,513.9,474.6,441.6;ESI-MS m/z for C15H16N2O3:273.05(M++H).
18.2、4-(6-甲基-吡嗪-2-基甲氧基)苯甲酸(AY18)的合成
按实施例13中13.3方法操作,得到AY18白色晶体,收率88.1%,m.p.207-209℃。
1H NMR(DMSO-d6,300MHz)δ:2.49(s,3H,CH3),5.28(s,2H,Pyr-CH2O-),7.13(d,2H,J=8.6Hz,3′,5′-Ar-H),7.90(d,2H,J=8.6Hz,2′,6′-Ar-H),8.53(s,1H,5″-Pyr-H),8.60(s,1H,3″-Pyr-H),12.63(s,1H,COOH);13C NMR(DMSO-d6,75.5MHz)δ:167.4,162.1,153.7,150.8,144.4,140.9,131.9,124.2,115.1,69.1,21.5;IR(KBr,cm-1)υ:2920.0,1689.3,1605.4,1540.7,1514.9,1427.3,1373.8,1273.6,1173.9,1117.6,1060.9,1021.4,995.4,928.0,855.6,773.0,733.3,694.1,655.3,532.0,503.3;ESI-MS m/z for C13H12N2O3:245.09(M++H).